相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review
F. Kunath et al.
WORLD JOURNAL OF UROLOGY (2020)
Management of patients with advanced prostate cancer in the Asia Pacific region: real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017
Edmund Chiong et al.
BJU INTERNATIONAL (2019)
PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a targeted approach
Emma Clarebrough et al.
WORLD JOURNAL OF UROLOGY (2019)
The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis
Niranjan J. Sathianathen et al.
WORLD JOURNAL OF UROLOGY (2019)
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
Liselotte M. S. Boeve et al.
EUROPEAN UROLOGY (2019)
Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
Padmanee Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart
Neha Vapiwala et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Karim Fizazi et al.
LANCET ONCOLOGY (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
N. W. Clarke et al.
ANNALS OF ONCOLOGY (2019)
Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review
Guillaume Ploussard et al.
EUROPEAN UROLOGY (2019)
Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis
Nicola Fossati et al.
EUROPEAN UROLOGY (2019)
Immunotherapy for lethal prostate cancer
Pasquale Rescigno et al.
NATURE REVIEWS UROLOGY (2019)
Treatment of the primary tumor in metastatic prostate cancer
Ye Yuan et al.
WORLD JOURNAL OF UROLOGY (2019)
Developments in oligometastatic hormone-sensitive prostate cancer
Ken Chow et al.
WORLD JOURNAL OF UROLOGY (2019)
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer
Niranjan J. Sathianathen et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
C. L. Vale et al.
ANNALS OF ONCOLOGY (2018)
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
M. R. Sydes et al.
ANNALS OF ONCOLOGY (2018)
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
Shankar Siva et al.
EUROPEAN UROLOGY (2018)
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Gwenaelle Gravis et al.
EUROPEAN UROLOGY (2018)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen et al.
EUROPEAN UROLOGY (2018)
Seven- Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
Lauren C. Harshman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
Noel Clarke et al.
LANCET ONCOLOGY (2018)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)
Edoardo Francini et al.
PROSTATE (2018)
Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands
Isabel Rauscher et al.
WORLD JOURNAL OF UROLOGY (2018)
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives
Claudia Mosillo et al.
CANCER TREATMENT REVIEWS (2018)
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis
Susan Feyerabend et al.
EUROPEAN JOURNAL OF CANCER (2018)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher C. Parker et al.
LANCET (2018)
Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography
Andrew Kneebone et al.
EUROPEAN UROLOGY ONCOLOGY (2018)
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
S. M. de Boer et al.
ANNALS OF ONCOLOGY (2018)
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
Larysa H. M. Rydzewska et al.
EUROPEAN JOURNAL OF CANCER (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
Marcello Tucci et al.
EUROPEAN UROLOGY (2016)
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
Gwenaelle Gravis et al.
EUROPEAN UROLOGY (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
Claire L. Vale et al.
LANCET ONCOLOGY (2016)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwenaelle Gravis et al.
LANCET ONCOLOGY (2013)
When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool
Alberto Briganti et al.
EUROPEAN UROLOGY (2010)
The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer:: a meta-analysis
A. M. Hovels et al.
CLINICAL RADIOLOGY (2008)
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162)
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
